8 completed. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
| Phase 2 | 1 | Completed 1 |
Follow Severe Hypertriglyceridemia: new trials by email Literature Review of Severe Hypertriglyceridemia trials Research Report on Severe Hypertriglyceridemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 311 | 2024-07-23 | 2026-10-09 |
| Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 446 | 2024-07-22 | 2026-10-08 |
| To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | 89bio, Inc. | 369 | 2023-06-15 | 2026-07-07 |
| A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 446 | 2022-08-31 | 2025-10-22 |
| A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 617 | 2021-10-25 | 2026-02-10 |
| Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function K-877, Fenofibrate, Placebo (for K-877) - Severe Hypertriglyceridemia | Phase 3 | Completed | Kowa Research Institute, Inc. | 551 | 2016-11-28 | 2022-11-30 |
| Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment K-877, Fenofibrate, Placebo (for K-877) - Severe Hypertriglyceridemia | Phase 3 | Completed | Kowa Research Institute, Inc. | 471 | 2016-11-26 | 2022-10-28 |
| Epanova® for Lowering Very High Triglycerides placebo, omefas - Severe Hypertriglyceridemia | Phase 2 / Phase 3 | Completed | AstraZeneca | 399 | 2011-01-01 | 2016-08-04 |
Hypertriglyceridemia (8) · Hyperlipidemias (3) · Dyslipidemias (2) · Metabolic Diseases (2) · Lipid Metabolism Disorders (1)
Nutritional and Metabolic Diseases (8) · Lipid Metabolism Disorders (7) · Dyslipidemias (6) · Metabolic Diseases (6) · Hyperlipidemias (5)
Fenofibrate (2) · K-877 compound (2) · olezarsen (2) · plozasiran (2)
Arrowhead Pharmaceuticals (2) · Ionis Pharmaceuticals, Inc. (2) · Kowa Research Institute, Inc. (2) · 89bio, Inc. (1) · AstraZeneca (1)
Hungary (8) · United States (8) · Bulgaria (7) · Czechia (7) · Poland (7) · Canada (5) · Spain (5) · Argentina (4) · France (4) · Italy (4) · Slovakia (4) · Belgium (3) · Brazil (3) · Georgia (3) · Germany (3)
Michael H Davidson, MD, FACC (1) · Teresa Parli, MD (1)
PMID 40064331, PMID 41211918, PMID 24528690
2023 (3)